Literature DB >> 23876679

Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection.

Nataraju Angaswamy1, Venkataswarup Tiriveedhi, Nayan J Sarma, Vijay Subramanian, Christina Klein, Jason Wellen, Surendra Shenoy, William C Chapman, T Mohanakumar.   

Abstract

Recent studies strongly suggest an increasing role for immune responses against self-antigens (Ags) which are not encoded by the major histocompatibility complex in the immunopathogenesis of allograft rejection. Although, improved surgical techniques coupled with improved methods to detect and avoid sensitization against donor human leukocyte antigen (HLA) have improved the immediate and short term function of transplanted organs. However, acute and chronic rejection still remains a vexing problem for the long term function of the transplanted organ. Immediately following organ transplantation, several factors both immune and non immune mechanisms lead to the development of local inflammatory milieu which sets the stage for allograft rejection. Traditionally, development of antibodies (Abs) against mismatched donor HLA have been implicated in the development of Ab mediated rejection. However, recent studies from our laboratory and others have demonstrated that development of humoral and cellular immune responses against non-HLA self-Ags may contribute in the pathogenesis of allograft rejection. There are reports demonstrating that immune responses to self-Ags especially Abs to the self-Ags as well as cellular immune responses especially through IL17 has significant pro-fibrotic properties leading to chronic allograft failure. This review summarizes recent studies demonstrating the role for immune responses to self-Ags in allograft immunity leading to rejection as well as present recent evidence suggesting there is interplay between allo- and autoimmunity leading to allograft dysfunction.
Copyright © 2013 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AEC; AGTR1; AMR; APC; Ab; Ag; BOS; CAN; CAV; CMV; CR; ColV; DC; DSA; HCV; HIF-1α; HLA; IRI; Kα1 tubulin; Kα1T; MHC; MHC class I related chain A; MICA; NHBE; OAD; OLT; PGD; TG; TRALI; Tx; airway epithelial cells; angiotensin II type 1 receptor; antibody; antibody mediated rejection; antigen; antigen presenting cell; bronchiolitis obliterans syndrome; cardiac allograft vasculopathy; chronic allograft nephropathy; chronic rejection; collagen V; cytomegalovirus; dendritic cells; donor specific antibodies; hepatitis C virus; human bronchial epithelial; human leukocyte antigen; hypoxia inducible factor; iNKT; invariant natural killer T cells; mTOR; major histocompatibility complex; mammalian target of rapamycin; obliterative airway disease; orthotopic liver transplantation; primary graft dysfunction; schemia/reperfusion injury; transfusion-related lung injury; transplant glomerulopathy; transplantation

Mesh:

Substances:

Year:  2013        PMID: 23876679      PMCID: PMC3813452          DOI: 10.1016/j.humimm.2013.07.002

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  103 in total

Review 1.  Chronic rejection and its risk factors.

Authors:  N L Tilney
Journal:  Transplant Proc       Date:  1999 Feb-Mar       Impact factor: 1.066

2.  Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation.

Authors:  T J Kroshus; V R Kshettry; K Savik; R John; M I Hertz; R M Bolman
Journal:  J Thorac Cardiovasc Surg       Date:  1997-08       Impact factor: 5.209

Review 3.  Cardiac allograft vasculopathy: a review.

Authors:  M Weis; W von Scheidt
Journal:  Circulation       Date:  1997-09-16       Impact factor: 29.690

4.  Glutamic acid decarboxylase antibodies are more frequent than islet cell antibodies in islet transplanted IDDM patients and persist or occur despite immunosuppression.

Authors:  C Jaeger; B J Hering; E Hatziagelaki; K Federlin; R G Bretzel
Journal:  J Mol Med (Berl)       Date:  1999-01       Impact factor: 4.599

5.  Identification of post-transplant anti-alpha 5 (IV) collagen alloantibodies in X-linked Alport syndrome.

Authors:  P Dehan; L P Van den Heuvel; H J Smeets; K Tryggvason; J M Foidart
Journal:  Nephrol Dial Transplant       Date:  1996-10       Impact factor: 5.992

6.  HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome.

Authors:  S Sundaresan; T Mohanakumar; M A Smith; E P Trulock; J Lynch; D Phelan; J D Cooper; G A Patterson
Journal:  Transplantation       Date:  1998-03-15       Impact factor: 4.939

7.  Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors.

Authors:  M A Antonysamy; W C Fanslow; F Fu; W Li; S Qian; A B Troutt; A W Thomson
Journal:  J Immunol       Date:  1999-01-01       Impact factor: 5.422

8.  Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice.

Authors:  G Benichou; A Valujskikh; P S Heeger
Journal:  J Immunol       Date:  1999-01-01       Impact factor: 5.422

9.  Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop.

Authors:  C F Verge; D Stenger; E Bonifacio; P G Colman; C Pilcher; P J Bingley; G S Eisenbarth
Journal:  Diabetes       Date:  1998-12       Impact factor: 9.461

10.  Primary pulmonary hypertension as a risk factor for the development of obliterative bronchiolitis in lung allograft recipients.

Authors:  V R Kshettry; T J Kroshus; K Savik; M I Hertz; R M Bolman
Journal:  Chest       Date:  1996-09       Impact factor: 9.410

View more
  24 in total

1.  Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation.

Authors:  Laura J Wozniak; Michelle J Hickey; Robert S Venick; Jorge H Vargas; Douglas G Farmer; Ronald W Busuttil; Sue V McDiarmid; Elaine F Reed
Journal:  Transplantation       Date:  2015-07       Impact factor: 4.939

2.  Tolerance induction using nanoparticles bearing HY peptides in bone marrow transplantation.

Authors:  Kelan A Hlavaty; Derrick P McCarthy; Eiji Saito; Woon Teck Yap; Stephen D Miller; Lonnie D Shea
Journal:  Biomaterials       Date:  2015-10-21       Impact factor: 12.479

3.  Pre-existing self-reactive IgA antibodies associated with primary graft dysfunction after lung transplantation.

Authors:  Vaidehi Kaza; Chengsong Zhu; Leying Feng; Fernando Torres; Srinivas Bollineni; Manish Mohanka; Amit Banga; John Joerns; T Mohanakumar; Lance S Terada; Quan-Zhen Li
Journal:  Transpl Immunol       Date:  2020-01-30       Impact factor: 1.708

4.  Antibody-mediated Rejection in Lung Transplantation.

Authors:  Hrishikesh S Kulkarni; Bradford C Bemiss; Ramsey R Hachem
Journal:  Curr Transplant Rep       Date:  2015-09-30

Review 5.  Chronic lung allograft dysfunction phenotypes and treatment.

Authors:  Stijn E Verleden; Robin Vos; Bart M Vanaudenaerde; Geert M Verleden
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

6.  The role of donor-specific antibodies in acute cardiac allograft dysfunction in the absence of cellular rejection.

Authors:  Nowell M Fine; Richard C Daly; Nisha Shankar; Soon J Park; Sudhir S Kushwaha; Manish J Gandhi; Naveen L Pereira
Journal:  Transplantation       Date:  2014-07-27       Impact factor: 4.939

7.  Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipients.

Authors:  Chisa Yamada; Daniel S Ramon; Marilia Cascalho; Randall S Sung; Alan B Leichtman; Milagros Samaniego; Robertson D Davenport
Journal:  Transfusion       Date:  2014-11-11       Impact factor: 3.157

Review 8.  Cellular and molecular targeting for nanotherapeutics in transplantation tolerance.

Authors:  Kelan A Hlavaty; Xunrong Luo; Lonnie D Shea; Stephen D Miller
Journal:  Clin Immunol       Date:  2015-03-21       Impact factor: 3.969

Review 9.  Antibodies against Angiotensin II Type 1 and Endothelin A Receptors: Relevance and pathogenicity.

Authors:  Mary Carmelle Philogene; Tory Johnson; Arthur Jason Vaught; Sammy Zakaria; Neal Fedarko
Journal:  Hum Immunol       Date:  2019-04-19       Impact factor: 2.850

Review 10.  Effector B cells in cardiac allograft vasculopathy.

Authors:  Emmanuel Zorn
Journal:  Curr Opin Organ Transplant       Date:  2019-02       Impact factor: 2.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.